TY  - JOUR
AU  - Grande, E
AU  - Alonso-Gordoa, T
AU  - Reig, O
AU  - Esteban, E
AU  - Castellano, D
AU  - Garcia-Del-Muro, X
AU  - Mendez, M J
AU  - Garcia-Donas, J
AU  - Gonzalez Rodriguez, M
AU  - Arranz-Arija, J A
AU  - Lopez-Criado, P
AU  - Molina-Cerrillo, J
AU  - Mellado, B
AU  - Alvarez-Fernandez, C
AU  - De Velasco, G
AU  - Cuellar-Rivas, M A
AU  - Rodriguez-Alonso, R M
AU  - Rodriguez-Moreno, J F
AU  - Suarez-Rodriguez, C
PY  - 2022
DO  - 10.1016/j.esmoop.2022.100463
UR  - http://hdl.handle.net/10668/22214
T2  - ESMO open
AB  - The INMUNOSUN trial had the objective of prospectively evaluating the efficacy and safety of sunitinib as a pure second-line treatment in patients with metastatic renal cell carcinoma (mRCC) who have progressed to first-line immune checkpoint...
LA  - en
PB  - Elsevier
KW  - Immune checkpoint inhibitors
KW  - Metastatic renal carcinoma
KW  - Second-line treatment
KW  - Sunitinib
KW  - Carcinoma, Renal Cell
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Kidney Neoplasms
KW  - Male
KW  - Prospective Studies
KW  - Sunitinib
TI  - Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
TY  - research article
VL  - 7
ER  -